nab-paclitaxel + capecitabine + eribulin mesylate + carboplatin

A combination of four chemotherapeutic agents used in the treatment of metastatic breast cancer. Each component has a distinct mechanism of action: - **Nab-paclitaxel**: A solvent-free, albumin-bound form of paclitaxel that inhibits microtubule dynamics - **Capecitabine**: An oral fluoropyrimidine prodrug that is converted to 5-fluorouracil in tumor tissue - **Eribulin mesylate**: A non-taxane microtubule dynamics inhibitor that prevents microtubule growth without affecting depolymerization - **Carboplatin**: A platinum-based agent that forms intrastrand DNA crosslinks This combination may be used in various regimens for treating advanced or metastatic breast cancer, particularly in pretreated patients or those with triple-negative disease.